Aswin Nagarajan*, Ramya Ravichandar
Nagarajan et al. J Clin Transl Res 2021; 7(6):12
Published online: November 29, 2021
Background and aim: Primary spinal cord glioblastoma multiforme (GBM) is a rare clinical condition and is often associated with dismal prognosis. The standard treatment is maximal safe surgery followed by adjuvant radiotherapy and chemotherapy. Despite such aggressive treatments, the median survival is estimated to be around 15 months in several studies. We report three patients with primary spinal glioblastoma multiforme who received treatment in our institute from 2012 to 2019. Among the three, one patient is on long term follow up with no evidence of disease, another patient succumbed to the illness and the third patient is having stable disease.
Relevance for patients: Although primary spinal glioblastoma multiforme is usually associated with dismal prognosis, our case series show a subset of patients will have a favorable outcome with the protocol treatment.
1.Department of Radiation Oncology, Cancer Institute(WIA), Adyar, Chennai, Tamil Nadu, India
2. Department of Pharmacology, Sree Balaji Medical College and Hospital, Chrompet, Chennai, Tamil Nadu, India
Department of Radiation Oncology, Cancer Institute(WIA), Adyar, Chennai, Tamil Nadu, India
Department of Pharmaceutics, Utrecht University, the Netherlands
Department of Pharmaceutics, Jiaxing University Medical College, Zhejiang, China
Full text PDF
Review process file (201.9 KB)